Login Register Cart 0
Research Article

糖尿病肾病患者同时评估microRNA 126和192以及这些microRNA与尿白蛋白的关系

卷 20, 期 5, 2020

页: [361 - 371] 页: 11

弟呕挨: 10.2174/1566524019666191019103918

价格: $65

摘要

背景与目的：糖尿病肾病（DN）是终末期肾病（ESRD）的主要决定因素。改变的microRNA水平会导致严重的慢性疾病，例如糖尿病。我们旨在测量DN中两种microRNA（microRNA126和192）的表达水平，并研究它们与蛋白尿水平的关系。 方法：该研究包括229名受试者（134名DN患者和95名对照）。测定血清脂质谱，葡萄糖水平，糖化血红蛋白（HbA1c）水平和肾功能。通过实时PCR确定microRNA126和microRNA192的表达水平。 结果：DN患者的体重，BMI值，葡萄糖水平（P <0.001），HbA1c水平（P <0.001），尿白蛋白-肌酐比值（ACR）值（P <0.001），尿素水平（P = 0.002）较高。 ，并且肌酐水平（P = 0.004）和microRNA192（P <0.001）和microRNA126（P <0.001）的表达水平均低于对照组。 MicroRNA126的表达与年龄，估计的肾小球滤过率（eGFR）和microRNA192的表达呈正相关，与血糖，HbA1c，尿素，肌酐和ACR呈负相关。 MicroRNA192的灵敏度（91％），特异性（94％）和曲线下面积（AUC）（0.967）值均高于microRNA126（灵敏度为90％;特异性为68％; AUC为0.897），因此可以准确诊断DN 。 结论：MicroRNA126和microRNA192的表达均与DN明显相关，并可能由于与大量白蛋白尿的密切关系而决定了疾病的进展。

关键词: 糖尿病肾病，微量白蛋白尿，MicroRNA，肾功能，尿白蛋白，肾病。

« Previous Next »
[1]
Saeedi Borujeni MJ, Esfandiary E, Taheripak G, Codoñer-Franch P, Alonso-Iglesias E, Mirzaei H. Molecular aspects of diabetes mellitus: Resistin, microRNA, and exosome. J Cell Biochem 2018; 119(2): 1257-72.
[http://dx.doi.org/10.1002/jcb.26271] [PMID: 28688216]
[2]
Zhang Y, Sun X, Icli B, Feinberg MW. Emerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy. Endocr Rev 2017; 38(2): 145-68.https://www.ncbi.nlm.nih.gov/pubmed/28323921
[http://dx.doi.org/10.1210/er.2016-1122] [PMID: 28323921]
[3]
Mohan A, Singh RS, Kumari M, et al. Urinary Exosomal microRNA-451-5p Is a Potential Early Biomarker of Diabetic Nephropathy in Rats. PLoS One 2016; 11(4) e0154055
[http://dx.doi.org/10.1371/journal.pone.0154055] [PMID: 27101382]
[4]
Delić D, Eisele C, Schmid R, et al. Urinary exosomal miRNA signature in type II diabetic nephropathy patients. PLoS One 2016; 11(3) e0150154
[http://dx.doi.org/10.1371/journal.pone.0150154] [PMID: 26930277]
[5]
Barutta F, Bellini S, Mastrocola R, Bruno G, Gruden G. MicroRNA and microvascular complications of diabetes. Int J Endocrinol 2018; 2018 6890501
[http://dx.doi.org/10.1155/2018/6890501] [PMID: 29707000]
[6]
Gonzalez Suarez ML, Thomas DB, Barisoni L, Fornoni A. Diabetic nephropathy: Is it time yet for routine kidney biopsy? World J Diabetes 2013; 4(6): 245-55.
[http://dx.doi.org/10.4239/wjd.v4.i6.245] [PMID: 24379914]
[7]
Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006; 13(12): 1097-101.
[http://dx.doi.org/10.1038/nsmb1167] [PMID: 17099701]
[8]
Ardekani AM, Naeini MM. The role of MicroRNAs in human diseases. Avicenna J Med Biotechnol 2010; 2(4): 161-79.
[PMID: 23407304]
[9]
Pandey AK, Agarwal P, Kaur K, Datta M. MicroRNAs in diabetes: tiny players in big disease. Cell Physiol Biochem 2009; 23(4-6): 221-32.https://www.karger.com/DOI/10.1159/000218169
[http://dx.doi.org/10.1159/000218169] [PMID: 19471090]
[10]
Bhatt K, Mi Q-S, Dong Z. microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles. Am J Physiol Renal Physiol 2011; 300(3): F602-10.
[http://dx.doi.org/10.1152/ajprenal.00727.2010] [PMID: 21228106]
[11]
Kato M, Arce L, Natarajan R. MicroRNAs and their role in progressive kidney diseases. Clin J Am Soc Nephrol 2009; 4(7): 1255-66.
[http://dx.doi.org/10.2215/CJN.00520109] [PMID: 19581401]
[12]
Ma X, Lu C, Lv C, Wu C, Wang Q. The expression of miR-192 and its significance in diabetic nephropathy patients with different urine albumin creatinine ratio. J Diabetes Res 2016; 2016 6789402
[http://dx.doi.org/10.1155/2016/6789402] [PMID: 26881255]
[13]
Krupa A, Jenkins R, Luo DD, Lewis A, Phillips A, Fraser D. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 2010; 21(3): 438-47.
[http://dx.doi.org/10.1681/ASN.2009050530] [PMID: 20056746]
[14]
Fang S, Ma X, Guo S, Lu J. MicroRNA-126 inhibits cell viability and invasion in a diabetic retinopathy model via targeting IRS-1. Oncol Lett 2017; 14(4): 4311-8.
[http://dx.doi.org/10.3892/ol.2017.6695] [PMID: 28943945]
[15]
Harvey SJ, Jarad G, Cunningham J, et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol 2008; 19(11): 2150-8.
[http://dx.doi.org/10.1681/ASN.2008020233] [PMID: 18776121]
[16]
Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107(6): 810-7.
[http://dx.doi.org/10.1161/CIRCRESAHA.110.226357] [PMID: 20651284]
[17]
Bijkerk R, Duijs JMGJ, Khairoun M, et al. Circulating microRNAs associate with diabetic nephropathy and systemic microvascular damage and normalize after simultaneous pancreas-kidney transplantation. Am J Transplant 2015; 15(4): 1081-90.
[http://dx.doi.org/10.1111/ajt.13072] [PMID: 25716422]
[18]
Wang H, Peng W, Shen X, Huang Y, Ouyang X, Dai Y. Circulating levels of inflammation-associated miR-155 and endothelial-enriched miR-126 in patients with end-stage renal disease. Braz J Med Biol Res 2012; 45(12): 1308-14.
[http://dx.doi.org/10.1590/S0100-879X2012007500165] [PMID: 23070235]
[19]
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15(7): 539-53.
[http://dx.doi.org/10.1002/(SICI)1096-9136(199807)15:7<539:AID-DIA668>3.0.CO;2-S] [PMID: 9686693]
[20]
Mueller P. MaryMacNell S, Jay S and Dayton T. Whitfield laboratory C, The analytical determination of the protein albumin in urine. Clin Chem 1991; 37(2): 191-5.
[PMID: 1993322]
[21]
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2)(Suppl. 1): S1-S266.
[PMID: 11904577]
[22]
Levey AS, Coresh J, Greene T, et al. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145(4): 247-54.
[http://dx.doi.org/10.7326/0003-4819-145-4-200608150-00004] [PMID: 16908915]
[23]
Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis 2014; 64(4): 510-33.
[http://dx.doi.org/10.1053/j.ajkd.2014.08.001] [PMID: 25257325]
[24]
Hostetter TH. Prevention of the development and progression of renal disease. J Am Soc Nephrol 2003; 14(7 (Suppl. 2): S144-7.
[http://dx.doi.org/10.1097/01.ASN.0000070150.60928.06] [PMID: 12819320]
[25]
Lv C, Zhou YH, Wu C, Shao Y, Lu CL, Wang QY. The changes in miR-130b levels in human serum and the correlation with the severity of diabetic nephropathy. Diabetes Metab Res Rev 2015; 31(7): 717-24.
[http://dx.doi.org/10.1002/dmrr.2659] [PMID: 25952368]
[26]
Al-Kafaji G, Al-Mahroos G, Al-Muhtaresh HA, Skrypnyk C, Sabry MA, Ramadan AR. Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker. Exp Ther Med 2016; 12(2): 815-22.
[http://dx.doi.org/10.3892/etm.2016.3395] [PMID: 27446281]
[27]
Chien H-Y, Chen C-Y, Chiu Y-H, Lin Y-C, Li W-C. Differential microRNA profiles predict diabetic nephropathy progression in Taiwan. Int J Med Sci 2016; 13(6): 457-65.https://www.ncbi.nlm.nih.gov/pubmed/27279796
[http://dx.doi.org/10.7150/ijms.15548] [PMID: 27279796]
[28]
Shao Y, Ren H, Lv C, Ma X, Wu C, Wang Q. Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease. Endocrine 2017; 55(1): 130-8.
[http://dx.doi.org/10.1007/s12020-016-1069-4] [PMID: 27522360]
[29]
Szeto C-C, Ching-Ha KB, Ka-Bik L, et al. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases. Dis Markers 2012; 33(3): 137-44.
[http://dx.doi.org/10.1155/2012/842764] [PMID: 22960330]
[30]
Wang G, Kwan BC-H, Lai FM-M, Chow K-M, Li PK-T, Szeto C-C. Urinary sediment miRNA levels in adult nephrotic syndrome. Clin Chim Acta 2013; 418: 5-11.
[http://dx.doi.org/10.1016/j.cca.2012.12.011] [PMID: 23313053]
[31]
Park S, Moon S, Lee K, Park IB, Lee DH, Nam S. Urinary and blood MicroRNA-126 and -770 are potential noninvasive biomarker candidates for diabetic nephropathy: a meta-analysis. Cell Physiol Biochem 2018; 46(4): 1331-40.
[http://dx.doi.org/10.1159/000489148] [PMID: 29689545]
[32]
Jaeger A, Zollinger L, Saely CH, et al. Circulating microRNAs -192 and -194 are associated with the presence and incidence of diabetes mellitus. Sci Rep 2018; 8(1): 14274.
[http://dx.doi.org/10.1038/s41598-018-32274-9] [PMID: 30250222]
[33]
Ezzat H, Lotfy AM, Attia FA, Mohamed GA, Tawfeek HM. Expression of micro RNA192 in type 2 diabetes mellitus relation to glycemic control, metabolic abnormalities, renal and ocular complications. Am J Biochem 2013; 3(4): 97-106.
[http://dx.doi.org/10.5923/j.ajb.20130304.03]
[34]
Rezk NA, Sabbah NA, Saad MSS. Role of MicroRNA 126 in screening, diagnosis, and prognosis of diabetic patients in Egypt. IUBMB Life 2016; 68(6): 452-8.
[http://dx.doi.org/10.1002/iub.1502] [PMID: 27118517]
[35]
Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27(2): 157-72.
[http://dx.doi.org/10.1002/sim.2929] [PMID: 17569110]
[36]
Gil-Zamorano J, Martin R, Daimiel L, et al. Docosahexaenoic acid modulates the enterocyte Caco-2 cell expression of microRNAs involved in lipid metabolism. J Nutr 2014; 144(5): 575-85.
[http://dx.doi.org/10.3945/jn.113.189050] [PMID: 24623846]
[37]
Hernández-Alonso P, Giardina S, Salas-Salvadó J, Arcelin P, Bulló M. Chronic pistachio intake modulates circulating microRNAs related to glucose metabolism and insulin resistance in prediabetic subjects. Eur J Nutr 2017; 56(6): 2181-91.
[http://dx.doi.org/10.1007/s00394-016-1262-5] [PMID: 27383196]
[38]
Jiang L, Huang J, Chen Y, et al. Identification of several circulating microRNAs from a genome-wide circulating microRNA expression profile as potential biomarkers for impaired glucose metabolism in polycystic ovarian syndrome. Endocrine 2016; 53(1): 280-90.
[http://dx.doi.org/10.1007/s12020-016-0878-9] [PMID: 26860517]
[39]
Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008; 15(2): 261-71.
[http://dx.doi.org/10.1016/j.devcel.2008.07.002] [PMID: 18694565]
[40]
Kato M, Arce L, Wang M, Putta S, Lanting L, Natarajan R. A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells. Kidney Int 2011; 80(4): 358-68.
[http://dx.doi.org/10.1038/ki.2011.43] [PMID: 21389977]
[41]
Feng X, Wang H, Ye S, et al. Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IκBα. PLoS One 2012; 7(12) e52782
[http://dx.doi.org/10.1371/journal.pone.0052782] [PMID: 23285182]
[42]
Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008; 105(40): 15535-40.
[http://dx.doi.org/10.1073/pnas.0808266105]
[43]
Feng R, Chen X, Yu Y, et al. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett 2010; 298(1): 50-63.
[44]
Crawford M, Brawner E, Batte K, et al. Nana-Sinkam SP MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun 2008; 373(4): 607-12.
[45]
Tan Y, Ge G, Pan T, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One 2014; 9(9) e107986
[http://dx.doi.org/10.1371/journal.pone.0107986] [PMID: 25238238]
[46]
Feinberg-Gorenshtein G, Guedj A, Shichrur K, et al. MiR-192 directly binds and regulates Dicer1 expression in neuroblastoma. PLoS One 2013; 8(11) e78713
[http://dx.doi.org/10.1371/journal.pone.0078713] [PMID: 24223844]
[47]
Jin Z, Selaru FM, Cheng Y, et al. MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene 2011; 30(13): 1577-85.
[http://dx.doi.org/10.1038/onc.2010.534] [PMID: 21119604]
[48]
Song B, Wang Y, Kudo K, Gavin EJ, Xi Y, Ju J. miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin Cancer Res 2008; 14(24): 8080-6.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-1422] [PMID: 19088023]
[49]
Schotte D, De Menezes RX, Akbari Moqadam F, et al. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 2011; 96(5): 703-11.
[http://dx.doi.org/10.3324/haematol.2010.026138] [PMID: 21242186]

Rights & Permissions Print Cite
Article Metrics
13
© 2025 Bentham Science Publishers | Privacy Policy